RheumaGen

Executive Summary

RheumaGen is a private biotechnology company pioneering a novel class of cell and gene therapies aimed at curing autoimmune diseases by targeting the human leukocyte antigen (HLA) genes, which are central to immune system regulation. Founded in 2019 and headquartered in San Diego, the company's approach involves editing these 'immune genes' to stop the immune system from attacking healthy cells, offering the potential for one-time, curative treatments for patients with refractory autoimmune conditions. While currently in early preclinical stages, RheumaGen's platform could address a wide range of autoimmune disorders, representing a paradigm shift from chronic management to definitive cures. The company is funded through private investment and has not yet disclosed its total funding or valuation. As a private entity, its progress is less transparent, but its focus on HLA editing distinguishes it from other gene therapy approaches. Key challenges include proving the safety and efficacy of in vivo gene editing in autoimmune contexts and navigating the regulatory pathway for a first-in-class therapy.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round Announcement80% success
• Q1 2027Preclinical Proof-of-Concept Data Release70% success
• Q2 2027IND Submission for Lead Candidate40% success